Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company GlobeNewswire December 02, 2025 BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that it intends to develop its fully human anti-IL-6 receptor (IL-6R) monoclonal antibody, […]